

**JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY**

INTERIM SEPARATE FINANCIAL STATEMENTS

From 01/04/2025 to 30/06/2025

CONTENTS

	Page
. Balance sheet as of 30 June 2025	3-4
. Income statement as of June 30, 2025	5
. Cash flow statement as of June 30, 2025	6 - 7
. Notes to the financial statements as of June 30, 2025	8-25

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

From 01/04/2025 to 30/06/2025

REPORT OF THE BOARD OF GENERAL DIRECTORS

The Board of General Directors of JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY (the "Company") presents its report and the Company's interim Separate financial statements period from 01/04/2025 to 30/06/2025.

THE COMPANY

Japan Vietnam Medical Investment and Development Joint Stock Company ("the Company") formerly was established under the Certificate of Business Registration No. 0101178800 dated 27 September 2010 issued by the Hanoi Department of Planning and Investment and registered for the 22st change on 14 July 2025.

The Company's head office is located at 24 Floor, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.

BOARD OF MANAGEMENT, BOARD OF GENERAL DIRECTORSS AND BOARD OF SUPERVISION

The member of the Board of Directors during the fiscal period and to the reporting date are:

Mr. Nguyen Hai Ha	Chairman	(To 21/04/2025)
Mr. Vu Khanh Din	Chairman	(Since 21/04/2025)
Mr. Pham Thanh Nam	Vice Chairman	
Mrs Nguyen Thi Hanh	Member of BOD	
Mr. Nguyen Thi Phuong	Member of BOD	
Mr. Nguyen Van Chi	Member of BOD	

The members of the Board of Management during the fiscal period and to the reporting date are:

- Mr. Vu Van Toan	CEO	(Since 24 April 2025)
- Mr. Pham Thanh Nam	CEO	(To 24 April 2025)
- Mr. Vu Van Toan	Deputy CEO	(To 24 April 2025)
- Mrs. Do Thi Ngoc Hoa	Deputy CEO	(To 1 April 2025)

The members of the Board of Supervision are:

Mr. Do Duc Hiep	Head	(Since 21 April 2025)
Mr. Nguyen Van Vy	Head	(To 21 April 2025)
Ms. Dang Thi Ha Giang	Member	
Ms. Nguyen Thi Tien Chi	Member	(To 21 April 2025)
Ms. Nguyen Vu Y Tan	Member	(Since 21 April 2025)

STATEMENT OF THE BOARD OF GENERAL DIRECTORS'S RESPONSIBILITY IN RESPECT OF THE INTERIM SEPARATE FINANCIAL STATEMENTS

The Board of General Directors is responsible for the interim Separate financial statements which give a true and fair view of the financial position of the Company, its operating results and its cash flows for the year. In preparing those interim Separate financial statements, the Board of General Directors is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the interim Separate financial statements;
- Prepare and present the interim Separate financial statements on the basis of compliance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of interim Separate financial statements;
- Prepare the interim Separate financial statements on going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of General Directors is responsible for ensuring that accounting records are kept to reflect the financial position of the Company, with reasonable accuracy at any time and to ensure that the interim Separate financial statements comply with the registered accounting system. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

We, The Board of General Directors, confirm that the interim Separate financial statements give a true and fair view of the financial position As at 30 June 2025, its operation results and cash flows in the period from 01/04/2025 to 30/06/2025 of the Company in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of interim Separate financial statements.



On behalf of the Board of Management

Vu Van Toan

General Director

Hanoi, 30 July 2025

Unit: VND

ASSETS	Codes	Notes	30 Jun 2025	01 Jan 2025
A - CURRENT ASSETS (100 = 110 + 120 + 130 + 140 + 150)	100		554,239,683,498	557,894,874,505
I. Cash and cash equivalents	110	5	18,439,775,965	18,565,353,017
1. Cash	111		17,019,775,965	18,415,353,017
2. Cash equivalents	112		1,420,000,000	150,000,000
II. Short-term investments	120		13,130,100,000	180,100,000
3. Investments held to maturity	123	6.1	13,130,100,000	180,100,000
III. Short-term receivables	130		368,330,188,698	385,418,335,040
1. Short-term trade receivables	131	7	138,898,990,598	369,809,235,800
2. Short-term advances to suppliers	132	8	24,447,130,873	326,789,504,655
3. Short-term loan receivables	135		7,800,000,000	8,700,000,000
4. Other short-term receivables	136	9	228,309,660,169	730,385,162,175
5. Allowance for doubtful debts	137		(31,125,592,942)	(1,050,265,567,590)
IV. Inventories	140	11	154,142,775,368	152,678,416,996
1. Inventories	141		174,440,605,262	171,977,173,435
2. Allowance for devalutaion of inventories	149		(20,297,829,894)	(19,298,756,439)
V. Other current assets	150		196,843,467	1,052,669,452
1. Short-term prepaid expenses	151	12	154,500,431	510,268,197
2. Value added tax deductibles	152		37,401,268	537,459,487
3. Other receivables from State Budget	153		4,941,768	4,941,768
B - NON-CURRENT ASSETS (200 = 210 + 220 + 230 + 240 + 250 + 260)	200		290,593,356,872	272,980,181,696
I. Long-term receivables	210		1,096,177,762	29,231,377,329
1. Long-term trade receivables	211		140,177,762	28,275,377,329
6. Other long-term receivables	216	9	956,000,000	111,706,000,000
7. Allowance for long-term doubtful receivables	219		-	(110,750,000,000)
II. Fixed assets	220		65,056,286,709	68,294,033,918
1. Tangible fixed assets	221	13	65,019,232,053	68,232,276,134
Historical cost	222		421,386,228,327	434,199,019,398
Accumulated depreciation	223		(356,366,996,274)	(365,966,743,264)
3. Intangible fixed assets	227	14	37,054,656	61,757,784
Historical cost	228		3,610,757,500	3,610,757,500
Accumulated depreciation	229		(3,573,702,844)	(3,548,999,716)
IV. Long-term assets in progress	240		8,776,726	1,713,425,261
2. Construction in progress	242	15	8,776,726	1,713,425,261
V. Long-term financial investments	250		217,550,000,000	164,750,000,000
1. Investments in subsidiaries	251		97,603,000,000	97,603,000,000
1. Investments in associates	252	6.3	750,000,000	750,000,000
2. Other long-term investments	253	6.2	192,800,000,000	140,000,000,000
3. Allowance for long-term investments	254		(73,603,000,000)	(73,603,000,000)
VI. Other long-term assets	260		6,882,115,675	8,991,345,188
1. Long-term prepaid expenses	261	12	6,882,115,675	8,991,345,188
TOTAL ASSETS (270 = 100 + 200)	270		844,833,040,370	830,875,056,201

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS (continued)
Period from 01/04/2025 to 30/06/2025

B01-DN/HN

Unit: VND

01 Jan 2025


RESOURCES	Mã số	30 Jun 2025	01 Jan 2025
C - LIABILITIES (300 = 310 + 330)	300	269,287,030,533	287,468,687,426
I. Current Liabilities	310	269,287,030,533	287,468,687,426
1. Short-term trade payables	311 16	52,297,410,767	87,711,095,057
2. Short-term prepayments from customers	312 17	7,595,833,250	11,672,686,600
3. Taxes and other payables to State Budget	313 18	12,277,258,986	25,316,866,145
4. Payables to employees	314	1,498,780,495	5,550,182,265
5. Short-term accrued expenses	315 19	6,971,179,497	9,008,734,799
7. Other short-term payables	319 20	863,330,262	1,946,821,070
8. Short-term loans and finance leases	320 21	180,276,534,281	140,628,685,046
9. Provison for short-term payables	321	7,506,702,995	5,633,616,444
D - EQUITY (400 = 410)	400	575,546,009,837	543,406,368,775
I. Owner's equity	410 22	575,546,009,837	543,406,368,775
1. Owner's contributed capital	411	1,125,001,710,000	1,125,001,710,000
- Ordinary shares with voting rights	411a	1,125,001,710,000	1,125,001,710,000
2. Share premium	412	402,288,328,850	402,288,328,850
5. Investment and development funds	418	19,211,235,252	19,211,235,252
5. Retained earnings	421	(970,955,264,265)	(1,003,094,905,327)
- Retained earnings until last period	421a	(1,003,094,905,327)	(1,046,644,605,784)
- Retained earnings of this period	421b	32,139,641,062	43,549,700,457
TOTAL RESOURCES (440 = 300 + 400)	440	844,833,040,370	830,875,056,201

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Ngoc Cuong

Hanoi, 30 Jul 2025

Chief Executive Officer



Vu Van Toan

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS
 Period from 01/04/2025 to 30/06/2025

B02-DN/HN

Period from 01/04/2025 to 30/06/2025						Unit: VND
ITEMS	Codes	Notes	Quarter II 2025	Quarter II 2024	Accumulated from the beginning to the end of this quarter (This year)	Accumulated from the beginning to the end of this quarter (Last year)
1. Revenue from goods sold and services rendered	01	24	131,198,391,176	149,686,594,531	303,854,957,620	265,309,600,439
2. Revenue deduction	02	25	56,790,476	5,100,000	151,076,190	5,100,000
3. Net Revenue from goods sold and services rendered	10		131,141,600,700	149,681,494,531	303,703,881,430	265,304,500,439
4. Cost of goods sold	11	26	102,262,851,411	113,919,937,532	229,442,413,880	200,703,174,590
5. Gross profit from goods sold and services rendered (20=10-11)	20		28,878,749,289	35,761,556,999	74,261,467,550	64,601,325,849
6. Financial income	21	27	(1,534,359,918)	4,714,054,022	4,463,570,797	10,231,094,807
7. Financial expenses	22	28	3,634,761,333	420,721,036	6,482,911,196	1,737,067,449
Of which: interest expense	23		2,321,304,840	1,191,051,302	4,417,513,966	2,637,510,093
9. Selling expenses	25	29	9,473,400,192	16,094,972,121	24,894,641,881	34,188,042,023
10. General and Administration expenses	26	30	9,107,258,029	11,973,099,795	18,769,104,574	20,897,853,822
11. Operating profit (30=20+(21-22)+24-(25+26))	30		5,128,969,817	11,986,818,069	28,578,380,696	18,009,457,362
12. Other income	31	31	6,430,487,558	(1,188,030,871)	11,708,155,193	5,906,025,708
13. Other expenses	32	32	33,697,023	787,067,329	233,771,747	985,349,074
14. Profit from other activities (40=31-32)	40		6,396,790,535	(1,975,098,200)	11,474,383,446	4,920,676,634
15. Accounting profit before tax (50=30+40)	50		11,525,760,352	10,011,719,869	40,052,764,142	22,930,133,996
16. Current corporate income tax	51	33	2,207,722,322	2,002,343,974	7,913,123,080	4,586,026,799
18. Profit after tax (60=50-51-52)	60		9,318,038,030	8,009,375,895	32,139,641,062	18,344,107,197
19. Profit after tax of Parent Company	61		9,318,038,030	8,009,375,895	32,139,641,062	18,344,107,197

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Ngoc Cuong

Chief Executive Officer



Vu Van Toan

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS
Period from 01/04/2025 to 30/06/2025
(Indirect Method)

B03-DN/HN

ITEMS	Codes	Notes	This period	Last period
I. Cash flows from operating activities				
<i>Profit before tax</i>	<i>01</i>		<i>40,052,764,142</i>	<i>22,930,133,996</i>
<i>Adjustment for</i>				
Depreciation and amortization and goodwill	02		9,537,793,047	16,870,561,420
Allowance and provisions	03		6,446,064,204	(1,638,430,972)
Foreign exchange gain (loss) upon revaluation of monetary items denominated in foreign currency	04		290,413,391	(220,578,571)
Gain/Loss from investing activities	05		(11,629,725,097)	(8,957,800,687)
Interest expenses	06		4,417,513,966	2,637,510,093
Other adjustments	07		5,802,197,704	-
<i>Operating profit before working capital movements</i>	<i>08</i>		<i>54,917,021,357</i>	<i>31,621,395,279</i>
Increase, decrease in receivables	09		6,100,921,617	22,616,565,210
Increase, decrease in inventories	10		(2,463,431,827)	(29,139,958,305)
Increase, decrease in payables (exclude interest expense, CIT)	11		(51,952,217,996)	1,853,133,864
Increase, decrease prepayments	12		2,464,997,279	3,112,693,333
Increase, decrease in trading securities	13		-	-
Interest paid	14		(4,429,172,379)	(2,667,982,836)
Corporate income tax paid	15		(15,651,839,350)	(3,274,909,239)
<i>Net cash from operating activities</i>	<i>20</i>		<i>(11,013,721,299)</i>	<i>24,120,937,306</i>
II. Cash flows from investing activities				
Acquisition of fixed assets and other long-term assets	21		(11,255,998,351)	(5,635,408,176)
Proceeds from disposals of fixed assets and	22		7,282,153,344	4,627,272,726
Cash outflow for lending, acquiring debt instruments of other entities	23		(12,950,000,000)	(275,600,000,000)
Cash recovered from lending, selling debt instruments of other entities	24		900,000,000	107,000,000,000
Cash outflow for investments in other entities	25		(334,057,961,434)	-
Cash recovered from investments in other entities	26		309,651,000,000	-
Interest earned, dividend and profit received	27		11,671,101,453	5,711,918,322
<i>Net cash from investing activities</i>	<i>30</i>		<i>(28,759,704,988)</i>	<i>(163,896,217,128)</i>

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS
Period from 01/04/2025 to 30/06/2025
(Indirect Method)

B03-DN/HN

ITEMS	Codes	Notes	This period	Last period
III. Cash flows from financial activities				
Proceeds from borrowings	33		254,105,683,103	102,190,679,459
Repayment for borrowings	34		(214,457,833,868)	(106,785,554,369)
<i>Net cash from financial activities</i>	<i>40</i>		<i>39,647,849,235</i>	<i>(4,594,874,910)</i>
Net cash during the period	50		(125,577,052)	(144,370,154,732)
Cash and cash equivalents at the beginning	60	-	18,565,353,017	151,569,877,551
Cash and cash equivalents at the ending	70	-	18,439,775,965	7,199,722,819

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Ngoc Cuong

Hanoi, 30 Jul 2025

Chief Executive Officer



Vu Van Toan

**JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY
NOTES TO FINANCIAL STATEMENT**

1.1. Structure of ownership

Japan Vietnam Medical Investment and Development Joint Stock Company ("the Company") formerly was Japan Medical Equipment Joint Stock Company, operated under the Certificate of Business Registration No. 0101178800 dated 27 September 2010 issued by the Hanoi Department of Planning and Investment and registered for the 22th change on 14 July 2025.

The Company's head office is located at Floor 24, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.

The Company's chartered capital is VND 1,125,001,710,000 equivalent to 112,500,171 shares, par value per share is VND 10,000.

Total employees of the group as at 30 June 2025 was 116 (at 01 April 2025 was 121)

1.2. Operating industry and principal activities

The Company's principal activities include:

- Wholesale of medical equipment and instruments;
- Lease of medical equipment and instruments;
- Associate investment medical equipments;
- General clinic, specialits clinic and dental clinic;
- Financial investment activities.

1.3. Normal production and business cycle

The Company's normal course of business cycle is no more than 12 months

1.4. Corporate structure

The Company have a branch located at No. 218 Tran Hung Dao Street, Cho Lon Ward, Ho Chi Minh City which operating in wholesales of medical machinery and equipments.

As at 30 June 2025, the Company have 02 subsidiaries and 01 associate company as follow:

Subsidiaries	Principal activites	Address	Ownership ratio	Voting right ratio
- Kyoto Medical Science Company Limited.,	No business operations in the first 6 months of the year	Floor 24, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.	100.00%	100%
- Vietnam Japan Medical Technology Investment Joint Stock Company	General clinic, specialits clinic and dental clinic	Floor 1, No. 163 Hoang Cau Street, Dong Da Ward, Ha Noi City.	99.00%	99%
Associates	Principal activites	Address	Ownership ratio	Voting right ratio
- Viet Tin Medical Equipment Joint Stock Company	Traing medical equipments	No. 19 Vo Van Tan Street, Xuan Hoa Ward, Ho Chi Minh City	25.00%	25%

2 ACCOUNTING PERIOD AND ACCOUNTING CURRENCY

2.1 The Company's fiscal year begins on 01 January and ends on 31 December.

2.2 The currency unit used in accounting period is Vietnam Dong (VND)

3 ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM APPLIED

These financial statements are the separate financial statements of the parent company - Japan Vietnam Medical Development and Investment Joint Stock Company prepared for the year ended 30 June 2025.

The financial statements are expressed in Vietnamese Dong (VND) and prepared under the accounting principles in conformity with the Vietnamese corporate accounting system issued in pursuance of Circular No. 200/2014/TT-BTC dated 22 December 2014, Circular No. 53/2016/TT-BTC dated 21 March 2016 of Ministry of Finance, Vietnamese Accounting Standards, and the relevant statutory requirements applicable to financial reporting.

4 Estimates

The significant accounting policies, which have been adopted by the Company in the preparation of these financial statements, are as follows:

4.1 Basis of preparation of financial statements

The financial statements are prepared on the accrual basis (except for the information related to cash flows), under historical cost principle, based on the assumption of going concern.

4.2 Estimates

The preparation of financial statements in conformity with Vietnamese accounting standards, the Vietnamese corporate accounting system, and the relevant statutory requirements applicable to financial reporting requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. The actual number incurred may differ from the estimates and assumptions

4.3 Cash and cash equivalent

Cash reflects the full existing amount of the Company at the end of the accounting period, comprising cash on hand, demand deposits and cash in transit.

Cash equivalents include short-term investments with maturity less than 03 months since the date of investment, which can be converted easily into a certain amount of cash without any risk in conversion into cash at the reporting date and recorded following Vietnamese Accounting Standard No. 24 - Cash flow statement

4.4 Conversion of foreign currencies

During the period, transactions arising in foreign currencies are converted into VND at exchange rates ruling at the transaction dates or accounting book exchange rate. Foreign exchange differences arising from these transactions are recognized in financial income (if gain) and financial expense (if loss). Monetary items denominated in foreign currencies are translated using exchange rate ruling at the balance sheet date. Foreign exchange differences arising from revaluation are reflected in the foreign exchange rate differences account and the balance of this account is transferred to the financial income (if profit) or financial expense (if loss) at the end of the accounting period.

4.5 Held to maturity investment

Reflecting the investments that the Company has intention and ability to hold to maturity with remaining maturity not exceeding 12 months (short-term) and more than 12 months (long-term) from the reporting date (except trading securities), including time deposits (including treasury bills, promissory notes), bonds, commercial papers, preference stocks which the issuer is obliged to buy at a certain time in the future, held-to-maturity loans for the purpose of collecting periodic interest, other kinds of debt securities (e.g. investment in buying bad debts, etc.) and other held-to-maturity investments, not including those already presented in the items such as "cash equivalents", "receivables from short-term borrowings" and "receivables from long-term borrowings".

Held-to-maturity investments are initially recognized at cost, including purchase price and expenses related to the purchase of investments such as brokerage fees, transaction, advisory, tax fees and bank charges ... After initial recognition, these investments are recorded at recoverable value.

Interest incurred after the date of purchase of held-to-maturity investments, profit upon disposals or sale of held-to-maturity investments are recorded in financial income. Interest received before the investment date is deducted from the cost at the date of purchase.

The Company bases on the remaining term from the reporting date to classify held-to-maturity investments as long-term or short-term and perform revaluation of monetary items denominated in foreign currencies under the principle presented in note No. 4.4.

When having strong evidence indicating part or all of the investments may not be recoverable and the losses can be measured reliably, these losses are recorded in financial expenses in the year and reduced directly to the value of the investments. Provision for held-to-maturity investments is similar to receivables unlikely to recover, is made similarly to bad debts according to note No. 4.7.

4.6 Other investment

Investments in subsidiaries:

Reflecting the investments which the Company holds more than 50% voting rights and the right to control and govern the financial and operating policies of the investee (subsidiary) to gain economic benefits from the operation of such enterprise or the Company holds less than 50% voting rights but has below conditions:

- The other investors agreed to offer for the Company more than 50% of the voting rights;
- The Company has the right to govern the financial and operating policies under a statute or agreement;
- The Company has the right to appoint or remove the majority of the members of the Board of Directors or equivalent management level;
- The Company has the right to cast the majority of votes at the meetings of the Board of Directors or equivalent management level.

Investments in associates:

Reflecting the investments which the Company directly or indirectly holds from 20% to under 50% voting shares of the investee (associated company) without any other agreement.

Associated company is the company which the Company has significant influence but does not have right to control over the financial policies and activities. Significant influence represents the right to participate in making policy decisions about financial policies and business operations of the investee but not control those policies.

4.7 Receivables and provision for doubtful debts

Receivables are monitored detailed under the original terms, remaining terms at the reporting date, the receivable objects, receivable foreign currencies and other factors for the Company's management purpose. The classification of receivables comprised of trade receivables, and other receivables shall comply with the principles:

- Trade receivables include commercial receivables incurred from purchase-sale transactions, including receivables from sale of exported goods under the trust for other entities;
- Other receivables include non-commercial or non-trading receivables, including: receivables from loan interests, deposit interests, amount paid on behalf of another party; receivables which the export trustor must collect from the trustee; receivables from penalties, compensation; advances; pledges, collaterals, deposits, assets lending...

The company bases on the remaining term at the reporting date receivables to classify as long-term or short-term and the revaluation of monetary items denominated in foreign currencies according to the principles as presented in the note No. 4.4.

Receivables are recognised not exceeding the recoverable value. Provision for doubtful debts is made for receivables that are overdue for six months or more, or when the debtor is in difficulty of solvency due to dissolution, bankruptcy, or similar difficulties in accordance with the prevailing corporate accounting system.

4.8 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost comprises purchase price, processing cost and other direct attributable expenses that have been incurred in bringing the inventories to their present location and condition. Net realisable value represents the estimated selling price less all estimated costs to completion and costs to be incurred in marketing, selling and distribution. Cost is calculated using the weighted average method. Inventories are recorded by perpetual method.

The provision for the devaluation of inventories is the excess of the inventories' cost over their net realizable value at the accounting year end and made in accordance with prevailing corporate accounting system.

4.9 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation. Tangible fixed assets are recognized under the historical cost.

The costs of tangible fixed assets arising from purchases and self-constructions comprise all costs of bringing the tangible fixed assets to their working condition for their intended use.

The cost of self-construction or manufactured assets are the actual construction or manufacturing cost plus installation and test running costs.

Costs incurred after initial recognition are recorded as increase in the historical cost of assets if they actually improve the current status in comparison with the initial standard status of the assets, such as:

- Parts of the tangible fixed asset are modified to extend their useful life or to increase their capacity; or
- Parts of the tangible fixed asset are upgraded to substantially increase product quality; or
- New technology process is applied to reduce operation expenses of the assets in comparison with before.

The costs incurred for repairs and maintenance aims to restore or maintain the ability to bring the economic benefits of the assets according to the initial standard status, do not meet one of the above conditions, are recognized in the operation costs during the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives in accordance with Circular No. 45/2013/TT-BTC dated 25/04/2013 of the Ministry of Finance. The estimated useful lives are as follows:

	Years
Buildings and structures	05
Machinery and equipment	03 - 12
Motor vehicles	06 - 10
Office equipment	03 - 06

4.10 Intangible assets and amortisation

Intangible assets comprise software and are stated at cost less accumulated amortization. Software is measured initially at purchase cost and is amortized on a straight-line basis over an estimated useful life from 03 years to 06 years.

4.11 Construction in progress

The construction in progress is recorded at cost, including expenses directly related to (including borrowing costs by the Company's accounting policy) properties in the course of construction for production, equipment installed for the purpose of manufacturing, rental and management as well as related expenses to repairs of fixed assets. Depreciation of these assets, on the same basis as other assets, commences when the assets are ready for their intended use.

4.12 Prepaid expenses

Prepaid expenses are expenses which have already been paid but relate to results of operations of multiple accounting periods. The Company's prepaid expenses include the value of tools and supplies, cost of repairing Machinery and Equipments and others

4.13 Payables

The payables are monitored detailed under the original terms, the remaining terms at the reporting date, the payable objects, type of payables denominated in foreign currency and other factors according to the Company's management purpose. The classification of payables such as trade payables, other payables must be implemented the following principles:

- Trade payables include commercial payables incurred from purchase-sale transactions, including payables when imported goods under the trust;
- Other payables include non-commercial or non-trading payables, including: payables for loan interest, dividend and earning payables; payables for financial investments; amount paid for the third party; amount which the trustor receives from relevant parties to pay under the entrusted import-export transactions; asset borrowings; payables for penalties, compensation; surplus assets without reason; payables for social insurance, medical insurance, unemployment insurance, trade union; collaterals, deposits received, etc.

The company bases on the remaining terms of payables at the reporting date to classify as long-term or short-term and perform revaluation of monetary items denominated in foreign currencies according to the principles as presented in the note No. 4.4.

The payables are recorded not less than the payment obligations. In the case of there is evidence that a loss likely occurs, the Company recognizes immediately a payable under the prudent principle.

4.14 Payable provisions

Provision for liabilities is recognized only if the following conditions are fulfilled: The Company is responsible for current liabilities (legal liability or joint liability) due to consequences of any happened event; Possible decrease in economic benefits requires the settlement of liabilities; and Provide a reliable estimation of liabilities' value.

Provision for liabilities is recorded at the best estimate of the amount paid for current liabilities as at the end of the accounting period.

4.15 Loans and finance lease liabilities

The loans and finance lease liabilities are monitored detailed for each loan object, loan agreement, and loan asset; for the term of loan and finance lease liabilities and type of foreign currency (if any). The loans and finance lease liabilities with the remaining term more than 12 months from the reporting date are presented as long-term loans and finance lease liabilities. The due loans and finance lease liabilities within the next 12 months from the reporting date are presented as short-term loans and finance lease liabilities

4.16 Borrowing costs

Borrowing costs include interests and other costs incurred directly related to the loans.

Borrowing cost is charged to operating expenses during the period when incurred, except for borrowing costs directly attributable to the construction or production of qualifying assets with appropriate time (more than 12 months) to put into use for the intended purposes or sales, which recorded in the value of capitalized assets whether it is subject to the fulfillment of certain conditions of Vietnamese Accounting Standard No. 16 - Borrowing cost. Borrowing costs directly attributable to the construction of fixed assets, investment properties can be capitalized even though the construction is less than 12 months.

4.17 Revenue recognition

**JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY**
NOTES TO FINANCIAL STATEMENT

Revenue from the sale of goods shall be recognized if it simultaneously meets the following conditions:

- (a) The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;
- (b) The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- (c) revenue has been determined with relative certainty. When contracts define that buyers are entitled to return products, goods purchased under specific conditions, the Company shall only record turnovers if such specific conditions no longer exist and buyers are not entitled to return products, goods (unless the customer is entitled to return the goods under the form of exchange for other goods or services);
- (d) The Company has gained or will gain economic benefits from the good sale transaction; and
- (e) It is possible to determine the costs related to the goods sale transaction.

Revenue recognition from services rendered if simultaneously satisfying the following conditions:

- (a) Revenue is measured reliably. When the contracts define that the customers are entitled to return service purchased under specific conditions, the Company shall only record revenue if such specific conditions do not exist and the customers are not entitled to return services provided;
- (b) The Company received or will receive economic benefits from the sale transactions;
- (c) The completed work is determined at the reporting date; and
- (d) Incurred costs for the transaction and the costs to complete the transaction of providing such services is determined.

Revenue from financial activities includes: comprises deposit interest, profit from bond investment, profit from financial investment cooperation contract, discounted payments, gains from foreign exchange differences and others (if any).

Other income reflects income arising from the events or separate transactions with normal business operations of the Company, besides the above revenue.

4.18 Taxation

Corporate income tax represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit before tax as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years (including loss carried forward, if any) and it further excludes items that are never taxable or deductible.

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities and its tax base in the financial statements and is recognized using the balance sheet method. Deferred tax liability should be recognized for all taxable temporary differences, and deferred tax asset shall be recognized when it is probable that taxable profit will be available against so that temporary differences are deductible.

Deferred tax is calculated at the tax rates that are expected to apply in the year when the liability is settled or the asset realized. Deferred tax is recognized in the income statement, and recognized in the equity only when it relates to items charged or credited directly to equity.

Deferred tax assets and liabilities are offset when the company has a legally enforceable right to set off current tax assets against current tax liabilities, and when the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same tax authority and the Company intends to settle its current tax assets and liabilities on a net basis.

The determination of the taxes borne by the Corporation is based on the current interpretation of tax regulations. However, these regulations are subject to periodic variation and their ultimate determination depends on the results of the tax authorities' examinations.

Other taxes are paid in accordance with the prevailing tax laws in Vietnam.

4.19 Related parties

The parties are regarded as related parties of the Company if they have the ability to control or exercise significant influence over the Company in making financial and operating decisions or have the same key management personnel or jointly managed by another Company.

Individuals with the direct or indirect voting rights can impact significantly to the Company, including close family members of these individuals (parents, spouses, children, siblings).

Key management personnel have authority and responsibility for planning, managing and controlling the operation of the Company: the directors, the managers of the Company and close family members of these individuals.

The companies managed by these individuals mentioned above with direct or indirect voting rights or through these rights they can have a significant impact on the Company, including the companies owned by the leaders or major shareholders of the Company and the companies have the same key management personnel.

5. Cash and cash equivalents

	30-Jun-25	01-Jan-25
Cash in bank	17,019,775,965	18,415,353,017
Total	17,019,775,965	18,415,353,017
Cash equivalents	1,420,000,000	150,000,000
Total Cash and cash equivalents	18,439,775,965	18,565,353,017

JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY
NOTES TO FINANCIAL STATEMENT

6 Financial investment

6.1 Short-term investments held to maturity

	30-Jun-25	01-Jan-25
	Value	Value
Term - Deposit	13,130,100,000	180,100,000
Total	13,130,100,000	180,100,000

6.2 Other short-term investments

	30-Jun-25	01-Jan-25
	Value Provision	Value Provision
<i>Investments in associates</i>	97,603,000,000 (72,853,000,000)	97,603,000,000 (72,853,000,000)
- Kyoto Medical Science Ltd.	72,853,000,000 (72,853,000,000)	72,853,000,000 (72,853,000,000)
Company		
- MIDS	24,750,000,000	24,750,000,000
<i>Investments in joint ventures</i>	750,000,000 (750,000,000)	750,000,000 (750,000,000)
- Viet Tin Medical Devices JSC	750,000,000 (750,000,000)	750,000,000 (750,000,000)
<i>Investments in other entities</i>	192,800,000,000	140,000,000,000
Company A	140,000,000,000	140,000,000,000
Company B	52,800,000,000	-
Total	291,153,000,000 (73,603,000,000)	238,353,000,000 (73,603,000,000)

6.3 Investments in associates

	30-Jun-25	01-Jan-25
	Value Provision	Value Provision
<i>Investments in joint ventures</i>	750,000,000 (750,000,000)	750,000,000 (750,000,000)
- Viet Tin Medical Devices JSC	750,000,000 (750,000,000)	750,000,000 (750,000,000)

7 Short-term trade receivables

	30-Jun-25	01-Jan-25
A1 Investment JSC	-	88,842,829,825
Huong Dong Comercial JSC	-	46,926,815,439
Triet Ton Tien Medical Devices JSC	-	17,538,520,392
16A Ha Dong Ltd Company	-	15,576,130,000
Medical Devices and Project Ltd Company	-	10,797,500,000
HOAN MY TECHNOLOGY DEVELOPMENT INVESTMENT COMPANY LIMITED	27,257,602,010	681,924,000
MIDS	12,049,844,452	3,961,898,460
Other Customers	99,591,544,136	185,483,617,684
Total	138,898,990,598	369,809,235,800

8 Short-term advances to suppliers

	30-Jun-25	01-Jan-25
JWB Co.	-	190,230,906,514
Nishimura Medical Instrument Co.,Ltd	-	29,872,783,121
Medical Devices Ltd Company	-	24,725,000,000
Kyoto Medical Science Co., Ltd.	-	23,763,256,592
RC Pharmaceutical and Medical Equipment Production & Trading Co., Ltd.	-	21,080,000,000
An Thanh Phat Medical Devices Ltd, Company	12,240,360,000	12,240,360,000
HAI PHAT MEDICAL EQUIPMENT COMPANY LIMITED	3,395,000,000	2,380,843,957
UNITED IMAGING HEALTHCARE HONG KONG LIMITED	2,942,258,000	-
Other Customers	5,869,512,873	22,496,354,471

JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY
NOTES TO FINANCIAL STATEMENT

		24,447,130,873	326,789,504,655
9	Total		
	Other receivables		
		30-Jun-25	01-Jan-25
	<i>Short-term</i>		
	Receivables from interests	292,075,791	7,676,099,434
	Advances	14,245,275,322	78,314,763,458
	Deposit	355,109,352	427,328,242
	Prepayments, guarantee and payment on behalf	-	403,295,265,000
	Shortage of assets awaiting resolution	-	3,464,052,986
	Receivable of BCC	213,225,000,000	236,200,000,000
	Others	192,199,704	1,007,653,055
	Total	228,309,660,169	730,385,162,175
	<i>Long-term</i>		
	Mortgages	956,000,000	956,000,000
	Triet Ton Tien Medical Devices JSC	-	110,750,000,000
	Total	956,000,000	111,706,000,000

(1) Amounts that Company prepaid, guarant, and paid on behalf relating to key managerial predecessors before 2015

(2) Capital contribution according to the Capital Contribution Contract for the medical associate project No 01/TTT-JVC/HĐGV on 22 September 2014 between JVC and Triet Ton Tien JSC to carry out the medical device associate project at the Hospital. Company defines that it can not gain benefit from this contract and made a provision of 100% for damages from 31 Mar 2016.

(3) Are financial investing cooperation amount with partners with a view to make profit, the cooperative periods are from 6 to 12 months

On March 26, 2025, the Company issued Resolution No. 2603/2025/NQ-HĐQT-JVC regarding to the write-off of fully provisioned bad debts, which have been transferred off-balance sheet for monitoring purposes. Total: 584.571.745.440 VND

10 DOUBTFUL DEBTS

Receivables that are overdue or not yet due but are doubtful of collection

	30/06/2025			01/01/2025		
	Historical cost	Allowance	Recoverable Amount	Historical cost	Allowance	Recoverable Amount
<i>Short-term receivables</i>						
A1 Investment JSC	-			88,842,829,825	(88,842,829,825)	-
Huong Dong Comercial JSC	-			46,926,815,439	(46,926,815,439)	-
Triet Ton Tien Medical Devices JSC	-			17,538,520,392	(17,538,520,392)	-
16A Ha Dong Ltd Company	-			15,576,130,000	(15,576,130,000)	-
Medical Devices and Project Ltd Company	-			10,797,500,000	(10,797,500,000)	-
Huu nghi Viet Duc Hospital	3,231,100,000	(1,615,550,000)	1,615,550,000			-
Song Viet Ltd. Company	1,896,450,000	(1,896,450,000)	-			-
Other Customers	5,472,841,615	(1,995,973,686)	3,476,867,929	74,388,136,878	(66,968,991,438)	7,419,145,440
<i>Advance payments to suppliers</i>						
JWB Co.	-			190,230,906,514	(190,230,906,514)	-
Kyoto Medical Science Co., Ltd.	-			23,763,256,592	(23,763,256,592)	-

JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY
NOTES TO FINANCIAL STATEMENT

Nishimura Medical Devices Ltd Company			-	29,872,783,121	(29,872,783,121)	-
RC Pharmaceutical and Medical Equipment Production & Trading Co., Ltd			-	24,725,000,000	(24,725,000,000)	-
Gold Lite Pte. Ltd			-	21,080,000,000	(21,080,000,000)	-
An Thanh Phat Medical Devices Ltd, Company	12,240,360,000	(12,240,360,000)	-			-
Toan Dan Law Firm Co., Ltd.	2,022,597,471	(2,022,597,471)	-			-
Other Customers			-	18,454,162,531	(13,915,227,044)	4,538,935,487
<i>Total value of overdue other receivables</i>						
Triet Ton Tien Medical Devices JSC (Short-term + Long-term)			-	426,110,806,472	(426,110,806,472)	-
Huong Dong Comercial JSC			-	87,934,458,528	(87,934,458,528)	-
Other Customers	11,354,661,785	(11,354,661,785)	-	81,881,142,225	(81,881,142,225)	-
Total	36,218,010,871	(31,125,592,942)	5,092,417,929	1,172,973,648,517	(1,161,015,567,590)	11,958,080,927

Long-term receivables and loans

MIDS	140,177,762	140,177,762	28,275,377,329	28,275,377,329
Total	140,177,762	140,177,762	28,275,377,329	28,275,377,329

11 Inventories

	30-Jun-25		01-Jan-25	
	Historical cost	Allowance	Historical cost	Allowance
Goods in transit	1,589,992,168	-	8,971,969,181	-
Work in progress	8,000,000	-	1,042,368,808	-
Goods for sales	157,300,959,069	(20,297,829,894)	158,034,417,380	(19,062,849,741)
Goods on consignment	15,541,654,025	-	3,928,418,066	(235,906,698)
Total	174,440,605,262	(20,297,829,894)	152,678,416,996	(19,298,756,439)

12 Prepaid expenses

	30-Jun-25	01-Jan-25
Short-term		
Dispatched tools and supplies	28,069,142	135,616,161
Others	126,431,289	374,652,036
Total	154,500,431	510,268,197
Long-term		
Dispatched tools and supplies	293,375,824	648,209,454
Spare parts and replacement components	1,755,641,870	2,607,372,023
Warehouse and structural repair expenses	4,833,097,981	5,464,056,239
Others		271,707,472
Total	6,882,115,675	8,991,345,188

JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY
NOTES TO FINANCIAL STATEMENT

13	Tangible fixed assets <i>Landscape note</i>		
14	Intangible fixed assets <i>Landscape note</i>		
15.	Long-term assets in progress	30-Jun-25	01-Jan-25
	Construction in progress	8,776,726	1,713,425,261
	Total	8,776,726	1,713,425,261
16	Short-term trade payables	30-Jun-25	01-Jan-25
		Outstanding balance	Repayment capability amount
	FujiFilm Vietnam Co.,Ltd	25,974,827,185	25,974,827,185
	Danh Medical Instruments	12,847,290,572	12,847,290,572
	Konica Minolta, Inc	8,456,766,885	8,456,766,885
	MERIT MEDICAL SINGAPORE PTD LTD	2,893,000,000	2,893,000,000
	Others	2,125,526,125	2,125,526,125
	Total	52,297,410,767	52,297,410,767
17	Prepayments from customers	30-Jun-25	01-Jan-25
	SAI GON NAM DINH GENERAL CLINIC JSC		4,892,500,000
	National Hospital of Pediatrics		1,797,075,000
	Tam Viet Technical Service Commercial Investing Co.,LTD		1,330,000,000
	108 Military Central Hospital		1,673,264,340
	Kien An hospital	1,692,450,000	
	Hoa Binh General Hospital	1,148,400,000	
	Duc Minh Joint Stock Company	855,000,000	
	Bach Mai Hospital	894,201,600	
	Phu Yen Provincial Health Care Center for Government Officials	840,000,000	
	Others	2,165,781,650	1,979,847,260
	Total	7,595,833,250	11,672,686,600
18	Taxes and other payables to State Budget <i>Landscape Notes</i>		
19	Short-term Accrued Expenses	30-Jun-25	01-Jan-25
	Profesional consulting expense	5,303,255,718	5,538,465,918
	Payables for BCC individuals		1,995,208,042
	Business Commission expense	1,546,310,209	1,341,788,856
	Interest Expense	121,613,570	133,271,983
	Total	6,971,179,497	9,008,734,799
20	Other payables		

**JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY**
NOTES TO FINANCIAL STATEMENT

Trade union fee, SHUI	244,486,786	867,104,158
Payables of received BCC capital	166,729,158	59,500,000
Deposits and collaterals received	59,500,000	1,020,216,912
Others	392,614,318	1,946,821,070
Total	863,330,262	

(1) Payables related to capital contributions received from individuals under business cooperation contracts for the purchase of assets located at hospitals.

21 Loans and finance leases

Landscape Notes

22 Changing in owner's equity

Landscape Notes

23 Equity

	30-Jun-25		01-Jan-25	
	VND	%	VND	%
Contributed capital	1,125,001,710,000	100%	1,125,001,710,000	100%
Total	1,125,001,710,000	100%	1,125,001,710,000	100%

Capital transactions with owners and dividend distribution, profit sharing:

	30-Jun-25	01-Jan-25
Paid-in equity	1,125,001,710,000	1,125,001,710,000
+ Opening balance	1,125,001,710,000	1,125,001,710,000
+ Ending balance	-	-
Dividend, profit distributed	-	-

24 Revenue from goods sold and services rendered

	This period	Last period
Revenue from goods sold	117,882,523,087	121,775,025,019
Revenue from services rendered	5,284,249,172	6,231,586,058
Other revenue	8,031,618,917	21,679,983,454
Total	131,198,391,176	149,686,594,531
Revenue from related parties	2,085,186,445	1,411,378,835
- MIDS	23,083,200	23,083,200
- Tasco Joint Stock Company	2,108,269,645	1,434,462,035
Total	2,108,269,645	1,434,462,035

25 Revenue deduction

	This period	Last period
Revenue deduction	56,790,476	5,100,000
Total	56,790,476	5,100,000

26 Cost of goods sold and services rendered

	This period	Last period
Cost of goods sold	96,383,628,467	99,562,988,147
Cost of services rendered	3,333,183,607	2,411,422,481
Cost of leasing investment properties	2,001,362,235	12,843,606,297
Allowance for devaluation of inventories	544,677,102	(898,079,393)
Total	102,262,851,411	113,919,937,532

27 Financial Income

	This period	Last period
Bank and loan interest	225,025,680	2,878,386,254
Profit from financial investment cooperation contract		773,223,081
Profit from financial investment cooperation contract		73,951,536
Profit from financial investment cooperation contract	(1,759,385,598)	988,493,151
Total	(1,534,359,918)	4,714,054,022

28 Financial Expenses

**JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY**
NOTES TO FINANCIAL STATEMENT

	This period	Last period
Interest expenses	2,321,304,840	1,191,051,302
Realised exchange loss	1,220,345,540	29,570,608
Unrealised exchange loss	93,110,953	
Provision for diminution in value of trading securities and impairment loss from investment		(799,900,874)
Total	3,634,761,333	420,721,036
29 Selling expenses	This period	Last period
Raw materials	(1,072,724,929)	262,385,771
Labour expenses	5,644,145,813	3,694,865,203
Depreciation expenses	(92,831,356)	2,344,922,561
Provision/Reversal of provision for product warranty	920,420,382	(436,883,304)
Expenses of outsourcing services	3,205,485,361	6,703,892,707
Other expenses in cash	868,904,921	3,525,789,183
Total	9,473,400,192	16,094,972,121
30 Administrative expenses	This period	Last period
Labour expenses	4,115,996,516	5,359,943,548
Tools and stationery expenses	279,469,200	79,681,841
Depreciation expenses	185,380,508	388,974,293
Provision expenses	1,395,053,072	2,254,051,700
Expenses of outsourcing services	1,647,686,817	1,610,391,821
Other expenses in cash	1,483,671,916	2,280,056,592
Cộng	9,107,258,029	11,973,099,795
31 Other income	This period	Last period
		(3,297,966,074)
Gain from liquidation, disposal of fixed assets	4,041,697,649	
Gains from revaluation of assets	2,388,801,470	2,109,924,798
Others	(11,561)	10,405
Total	6,430,487,558	(1,188,030,871)
32 OTHER EXPENSES	This period	Last period
Loss from liquidation, disposal of fixed assets		605,721,499
Others	33,697,023	181,345,830
Cộng	33,697,023	787,067,329
33 Corporate income tax expense	This period	Last period
Corporate income tax expense calculated on taxable income for	2,207,722,322	2,002,343,974
Total current corporate income tax expense	2,207,722,322	2,002,343,974

Current corporate income tax payable is determined based on the taxable income for the current year. The Company's taxable income differs from the profit or loss reported in the Statement of Profit or Loss because taxable income excludes items of income and expenses that are subject to taxation or deductible in other periods, as well as items that are non-taxable or non-deductible for tax purposes. The current corporate income tax payable is calculated using the tax rates enacted as of the end of the interim reporting period.

34 OFF STATEMENT OF FINANCIAL POSITION ITEMS

Foreign currencies

	30/06/2025	01/01/2025
- USD	100	100

Doubtful debts written-off

Object	Value	Solving Time	Reason
Trade receivables	59,267,731,518	31/03/2025	Unrecoverable
Other receivables	13,612,130,439	31/03/2025	Unrecoverable
Trade receivables	240,679,310,430	31/03/2025	Unrecoverable
Advances to suppliers	307,847,523,800	31/03/2025	Unrecoverable

**JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY**
NOTES TO FINANCIAL STATEMENT

Other receivables	584,571,745,440	31/03/2025	Unrecoverable
-------------------	-----------------	------------	---------------

35 SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

Outstanding balances up to the reporting date are as follows:

Relation		30/06/2025	01/01/2025
		VND	VND
Short-term prepayments to suppliers			
- Kyoto Medical Science Ltd.	Subsidiary company		23,763,256,592
Other short-term receivables			
- MIDS	Subsidiary company	12 049 844 452	27,413,274,667
- Tasco Joint Stock Company	Related Company	34 127 520	32,918,400
Short-term prepayments from			
- MIDS	Subsidiary company		11,200,000,000
Short-term prepayments from			
- MIDS	Subsidiary company	3 100 000 000	

Transactions with Related Parties as follow:

Remuneration of the Board of Directors, the Board of Supervisors, and the Board of Management

Preparer

Chief Accountant

This Period

Last Period

1,017,600,000

1,397,627,791

Chief Executive Officer



Nguyen Thi Lua



Nguyen Ngoc Cuong



Vu Van Toan

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS
 Period from 01/04/2025 to 30/06/2025

13 Tangible Fixed Assets

	Buildings and structures	Machinery	Office Equipments	Transportation Vehicle	Others	Total
	VND	VND	VND	VND	VND	VND
HISTORICAL COST						
Balance on 01/01/2025	4,695,208,182	416,923,279,599	3,140,438,021	9,440,093,596	-	434,199,019,398
Purchasing	-	5,259,802,331	325,010,488	1,573,636,363	-	7,158,449,182
Increase due to consolidation	-	-	-	-	-	-
Construction in progress	-	-	-	-	-	-
Reclassification	-	-	-	-	-	-
Liquidation, disposal	-	(16,738,439,073)	-	-	-	(16,738,439,073)
Other increase/decrease	-	(3,232,801,180)	-	-	-	(3,232,801,180)
Balance on 30/06/2025	4,695,208,182	402,211,841,677	3,465,448,509	11,013,729,959	-	421,386,228,327
ACCUMULATED DEPRECIATION						
Balance on 01/01/2025	2,967,027,923	356,800,528,395	1,652,239,939	4,546,947,007	-	365,966,743,264
Depreciation	469,520,820	8,310,090,138	186,248,890	547,230,071	-	9,513,089,919
Increase due to consolidation	-	-	-	-	-	-
Reclassification	-	-	-	-	-	-
Liquidation, disposal	-	(16,086,699,423)	-	-	-	(16,086,699,423)
Other increase/decrease	-	(3,026,137,486)	-	-	-	(3,026,137,486)
Balance on 30/06/2025	3,436,548,743	345,997,781,624	1,838,488,829	5,094,177,078	-	356,366,996,274
CARRYING AMOUNT						
Balance on 01/01/2025	1,728,180,259	60,122,751,204	1,488,198,082	4,893,146,589	-	68,232,276,134
Balance on 30/06/2025	1,258,659,439	56,214,060,053	1,626,959,680	5,919,552,881	-	65,019,232,053

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS
Period from 01/04/2025 to 30/06/2025

14 Intangible fixed assets	Unlimited-term land use rights		Limited-term land use rights		Software	Others	Total
	VND	VND	VND	VND			
HISTORICAL COST							
Balance on 01/01/2025	-	-	-	3,610,757,500	-	-	3,610,757,500
Purchasing	-	-	-	-	-	-	-
Increase due to consolidation	-	-	-	-	-	-	-
Liquidation, disposal	-	-	-	-	-	-	-
Balance on 30/06/2025	-	-	-	3,610,757,500	-	-	3,610,757,500
ACCUMULATED DEPRECIATION							
Balance on 01/01/2025	-	-	-	3,548,999,716	-	-	3,548,999,716
Depreciation	-	-	-	24,703,128	-	-	24,703,128
Increase due to consolidation	-	-	-	-	-	-	-
Other increase/decrease	-	-	-	-	-	-	-
Liquidation, disposal	-	-	-	-	-	-	-
Balance on 30/06/2025	-	-	-	3,573,702,844	-	-	3,573,702,844
CARRYING AMOUNT							
Balance on 01/01/2025	-	-	-	61,757,784	-	-	61,757,784
Balance on 30/06/2025	-	-	-	37,054,656	-	-	37,054,656

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS
Period from 01/04/2025 to 30/06/2025

18 Taxes and other payables to State Budget	Opening balance		Arising during period		Ending Balance	
	Receivables	Payables	Payable amount	Paid amount	Increase due to consolidation	Decrease due to consolidation
	01/01/2025	01/01/2025	VND	VND	VND	VND
- Output VAT	-	2,633,648,855	5,474,345,342	7,424,216,070	-	-
- VAT of imported goods	-	-	2,608,629,380	2,608,629,380	-	-
- Special consumption tax	-	-	-	-	-	-
- Importing and exporting tax	-	-	158,958,542	158,958,542	-	-
- Corporate income tax	-	19,132,166,841	7,913,123,080	15,651,839,350	-	-
- Personal income tax	-	231,375,293	3,400,017,835	3,431,362,840	-	-
- Resource tax	-	-	-	-	-	-
- Real estate tax, land rent	-	-	-	-	-	-
- Environmental protection tax and other taxes	4,941,768	3,319,675,156	1,377,360	3,321,052,516	-	4,941,768
Total	4,941,768	25,316,866,145	19,556,451,539	32,596,058,698	-	12,277,258,986

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS

Period from 01/04/2025 to 30/06/2025

21	Loans and finance leases	01/01/2025		During period		30/06/2025
		VND		VND		
		Value/Repayment Capability	Increase	Decrease	Value/Repayment Capability	
Short-term loans		140,628,685,046	256,603,053,373	216,955,204,138	180,276,534,281	
		14,124,403,946	30,450,517,878	31,901,589,987	12,673,331,837	
BIDV - My Dinh Branch (1)		64,640,719,208	56,548,699,893	72,640,719,208	48,548,699,893	
MB - So giao dich 1 Branch (2)		16,992,576,804	66,713,165,220	41,393,988,755	42,311,753,269	
Vietcombank - Ha Thanh Branch (3)		25,449,365,096	49,015,874,110	35,350,663,619	39,114,575,587	
Vietinbank - Thang Long Branch (4)		8,734,617,834	-	8,734,617,834	-	
ABBank - Hanoi Branch (5)		10,687,002,158	42,441,136,350	26,933,624,735	26,194,513,773	
TPBank - Hanoi Branch (6)		-	11,433,659,922	-	11,433,659,922	
VPBank - Ngo Quyen Branch (7)						
Total		140,628,685,046	256,603,053,373	216,955,204,138	180,276,534,281	

Detailed information related to loans

(1) Loan under credit contract No. 01/2024/6453135/HDTD dated July 11, 2024 between the Company and Vietnam Joint Stock Commercial Bank for Investment and Development - My Dinh Branch. The total credit limit is VND 35,000,000,000. The purpose of the loan is to supplement working capital for the Company's regular production and business activities. The loan interest rate is specified in each debt acknowledgment contract. The loan collateral is a term deposit contract and the Company's fixed assets.

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS

B09-DN/HN

Period from 01/04/2025 to 30/06/2025

(2) Loan under credit contract No. 233293.24.002.449769.TD dated July 23, 2024 and 311578.25.002.449769.TD dated June 26, 2025 between the Company and Military Commercial Joint Stock Bank - Transaction Office Branch 1. The total loan limit is VND 140,000,000,000, the loan term is until June 26, 2026. The purpose of the loan is to supplement working capital for the Company's regular production and business activities. The loan interest rate is specifically stipulated in each debt acknowledgment contract. The loan is secured by machinery, equipment, goods, and the right to collect receivables owned by Vietnam Japan Medical Investment and Development Joint Stock Company.

(3) Loan under Credit Agreement No. 24/8767425-CTD/017 dated May 13, 2024 and 24/8767425-CTD/018 dated May 20, 2025 between the Company and Joint Stock Commercial Bank for Foreign Trade of Vietnam - Ha Thanh Branch. The total credit limit is VND 45,000,000,000. The purpose of the loan is to supplement working capital for the Company's regular production and business activities. The loan interest rate is specifically stipulated in each debt acknowledgment contract. The collateral for the loan is the deposit contracts and fixed assets, real estate of the Company and third parties.

(4) Loan under Credit Agreement No. 05/2024-HDCVHM/NHCT236-VIETNHAT dated May 15, 2024 and 06/2025/HDCVHM/NHCT326-VIETNHAT dated June 06, 2025 between the Company and Vietnam Joint Stock Commercial Bank for Industry and Trade - Thang Long Branch. The total credit limit is VND 120,000,000,000. The purpose of the loan is to supplement working capital for the Company's regular production and business activities. The loan interest rate is specifically stipulated in each debt acknowledgment contract. The loan collateral is real estate and fixed assets of the Company and third parties.

(5) Loan under Loan Agreement No. 817/24/TD/SME/011 dated July 16, 2024 between the Company and An Binh Commercial Joint Stock Bank - Hanoi Branch. Total credit limit is 70,000,000,000 VND. The Company fully settled all loans in Q1/2025 and currently has no outstanding debt.

(6) The loan was granted under Credit Contract No. 537/2024/HDTD/DDO dated 11 November 2024 between the Company and Tien Phong Commercial Joint Stock Bank - Hanoi Branch. The total credit limit is VND 120,000,000,000, with a term of 06 months from the disbursement date.

(7) The loan was granted under Credit Contract No. 0901/2025 dated 09 January 2025 between the Company and Vietnam Prosperity Joint Stock Commercial Bank - Ngo Quyen Branch. The total credit limit is VND 50,000,000,000. The disbursed loan amount is VND 11,433,659,922, with a term of 06 months from the disbursement date.

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
INTERIM SEPARATE FINANCIAL STATEMENTS
Period from 01/04/2025 to 30/06/2025

B09-DN/HN

22. Changing in owner's equity

	Paid-in capital of owners	Share premium	Other capital of owners	Treasury stock	Retained Earnings	Non-controlling interest	Total
	VND	VND	VND	VND	VND	VND	VND
<i>Period from 01/04/2025 to 30/06/2025</i>							
Balance on 01/01/2025	1,125,001,710,000	402,288,328,850	19,211,235,252	-	(1,003,094,905,327)	-	543,406,368,775
Profit of the year	-	-	-	-	32,139,641,062	-	32,139,641,062
Balance on 30/06/2025	<u>1,125,001,710,000</u>	<u>402,288,328,850</u>	<u>19,211,235,252</u>	<u>-</u>	<u>(970,955,264,265)</u>	<u>-</u>	<u>575,546,009,837</u>